PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE
Clinical safety rating: safe
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
Pseudoephedrine is a sympathomimetic amine that acts as an indirect agonist at alpha- and beta-adrenergic receptors, causing vasoconstriction in the nasal mucosa and bronchodilation. Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms such as sneezing, rhinorrhea, and pruritus.
| Metabolism | Pseudoephedrine undergoes partial hepatic metabolism via N-demethylation to inactive metabolites; roughly 70-90% is excreted unchanged in urine. Triprolidine is extensively metabolized in the liver via hydroxylation and conjugation; its metabolism involves CYP450 enzymes, likely CYP3A4. |
| Excretion | Pseudoephedrine: ~70-90% renal as unchanged drug, minor hepatic metabolism (N-demethylation); Triprolidine: extensively hepatic metabolized, renal elimination of metabolites and unchanged drug (<5% unchanged), total excretion primarily renal and biliary. |
| Half-life | Pseudoephedrine: 5-8 hours (pH-dependent; alkaline urine increases half-life); Triprolidine: approximately 2-4 hours. Combined product: pseudoephedrine half-life is clinically relevant for dosing frequency. |
| Protein binding | Pseudoephedrine: ~50-70% bound to albumin and alpha-1 acid glycoprotein; Triprolidine: approximately 90% bound to plasma proteins. |
| Volume of Distribution | Pseudoephedrine: 2.5-3.5 L/kg; Triprolidine: 3-4 L/kg. Both indicate extensive tissue distribution, with pseudoephedrine distributing into breast milk and crossing blood-brain barrier. |
| Bioavailability | Pseudoephedrine: ~90% oral bioavailability; Triprolidine: ~95% oral bioavailability (first-pass metabolism minimal for triprolidine). |
| Onset of Action | Oral: Pseudoephedrine onset ~30-60 minutes; Triprolidine onset ~1-2 hours. |
| Duration of Action | Pseudoephedrine: 4-6 hours (immediate-release); Triprolidine: 4-6 hours. Product typically dosed every 4-6 hours. |
1 tablet (pseudoephedrine HCl 60 mg + triprolidine HCl 2.5 mg) orally every 4-6 hours, not to exceed 4 doses in 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR <30 mL/min: Avoid use. GFR 30-60 mL/min: Extend dosing interval to every 8-12 hours. GFR ≥60 mL/min: No adjustment. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Caution, consider extended interval (every 8-12 hours). Child-Pugh C: Avoid use due to reduced clearance and risk of toxicity. |
| Pediatric use | Children 6-12 years: 1/2 tablet (pseudoephedrine HCl 30 mg + triprolidine HCl 1.25 mg) every 4-6 hours, max 2 doses/24 hours. Children >12 years: Same as adult. Children <6 years: Not recommended. |
| Geriatric use | Initiate at lowest dose (1/2 tablet) every 6-8 hours due to increased sensitivity, reduced renal function, and higher risk of anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
| FDA category | Animal |
| Breastfeeding | Pseudoephedrine excreted into breast milk (M/P ratio ~2.6-3.8); triprolidine excretion minimal. May reduce milk production via prolactin suppression. Use with caution; monitor infant for irritability, poor feeding. |
| Teratogenic Risk | Limited human data; pseudoephedrine has been associated with gastroschisis in first trimester; triprolidine considered low risk. FDA Pregnancy Category C (pseudoephedrine) and B (triprolidine). First trimester: avoid due to potential vascular disruption; second/third trimester: use only if clearly needed, may reduce uterine blood flow and cause fetal tachycardia. |
■ FDA Black Box Warning
None
| Common Effects | Sedation |
| Serious Effects |
["Hypersensitivity to pseudoephedrine, triprolidine, or any component of the formulation","Severe hypertension or coronary artery disease","Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)","Narrow-angle glaucoma","Urinary retention","Severe renal impairment","Pregnancy (especially first trimester; risk of fetal harm)","Breastfeeding (potential for adverse effects in infants)"]
| Precautions | ["Use with caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, or urinary retention due to sympathomimetic effects.","May cause CNS stimulation, including insomnia, dizziness, or nervousness, especially in children.","Avoid excessive dosage or prolonged use; may cause rebound congestion.","Use with caution in patients with asthma, COPD, or respiratory depression; antihistamines may thicken bronchial secretions."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; fetal heart rate monitoring with prolonged use; assess amniotic fluid index if used near term. |
| Fertility Effects | No significant effects on fertility reported in humans; animal studies show no impairment. |